tirzepatide ban update FDA Grants a New Indication for Obesity Management Eli Lilly sues companies selling

Tan M, Li J, Xu HE, Melcher K, Yong EL

Ophthalmic Res

153 Injection of GDF-6 in the early stages of IDD can prevent the loss of ECM proteins and retain greater hydration and cells in the NP

10.1161/JAHA.115.003048 246

Cagrilintide Reconstitution Cagrilintide - dose per draw at common vial sizes Vial Size 5 mg BAC Water 2.0 mL Concentration 2.5 mg/mL 0.25 mg 0.10 mL (10 units) 0.5 mg 0.20 mL (20 units) 1.0 mg 0.40 mL (40 units) 2.4 mg 0.96 mL (96 units) Vial Size 10 mg BAC Water 2.0 mL Concentration 5.0 mg/mL 0.25 mg 0.05 mL (5 units) 0.5 mg 0.10 mL (10 units) 1.0 mg 0.20 mL (20 units) 2.4 mg 0.48 mL (48 units) Vial Size 10 mg BAC Water 1.0 mL Concentration 10.0 mg/mL 0.25 mg 0.025 mL (2.5 units) 0.5 mg 0.05 mL (5 units) 1.0 mg 0.10 mL (10 units) 2.4 mg 0.24 mL (24 units) Cagrilintide is sensitive - inject BAC water down the vial wall and swirl gently

Tehrani Fateh S, Moradi L, Kohan E, Hamblin MR, Shiralizadeh DA